

Att 31. 42. The method according to claim 39, wherein said modulator is an antibody.

AB 32. 43. The method according to claim 41, wherein said polypeptide is provided as part of a membrane fraction.

AB 33. 44. The method according to claim 39, wherein said HIV virus is HIV-1 or HIV-2

AB 34. 45. The method according to claim 39, wherein said HIV virus is a macrophage-trophic (M trophic or R5) strain virus.

AB 35. 46. The method according to claim 39, wherein said decreasing of infectivity is monitored by measuring a modification of the signaling activity of said CCR5 chemokine receptor.

AB 36. 47. The method according to claim 46, wherein said measuring of signaling activity comprises measuring of one or more of: changes in levels of cellular acidification, intracellular calcium, IP₃, and stimulation of an intracellular cascade.

AB 37. 48. The method according to claim 39, wherein said decreasing of infectivity is monitored by measuring production of an HIV polypeptide.

AB 38. 49. The method according to claim 48, wherein said HIV polypeptide is p24.

AB 39. 50. A CCR5 chemokine receptor modulator which decreases the infectivity of a cell expressing said CCR5 chemokine receptor by at least two-fold when delivered to said cell.

AB 40. 51. The CCR5 chemokine receptor modulator according to claim 50, wherein said modulator is an antibody.

REMARKS

Upon entry of this amendment, claims 39 to 51 are pending. No new matter is introduced